• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Metastatic Ovarian Cancer - Pipeline Review, H2 2012 Product Image

Metastatic Ovarian Cancer - Pipeline Review, H2 2012

  • ID: 2298914
  • October 2012
  • 45 pages
  • Global Markets Direct

Metastatic Ovarian Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Metastatic Ovarian Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Ovarian Cancer. Metastatic Ovarian Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Metastatic Ovarian Cancer.
- A review of the Metastatic Ovarian Cancer products under READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Metastatic Ovarian Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Metastatic Ovarian Cancer 7
Metastatic Ovarian Cancer Therapeutics under Development by Companies 9
Metastatic Ovarian Cancer Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Metastatic Ovarian Cancer Therapeutics – Products under Development by Companies 14
Metastatic Ovarian Cancer Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Metastatic Ovarian Cancer Therapeutics Development 16
F. Hoffmann-La Roche Ltd. 16
Sanofi-Aventis 17
Daiichi Sankyo Company, Ltd 18
Cell Therapeutics, Inc. 19
Northwest Biotherapeutics, Inc. 20
NewLink Genetics Corporation 21
Metastatic Ovarian Cancer – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
brostallicin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
bevacizumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
DCVax-Ovarian - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Docetaxel + Carboplatin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CS-1008 + Paclitaxel + Carboplatin - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ISIS-5132 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NLG8189 + Taxotere - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Metastatic Ovarian Cancer Therapeutics – Drug Profile Updates 39
Metastatic Ovarian Cancer Therapeutics - Dormant Products 40
Metastatic Ovarian Cancer – Product Development Milestones 41
Featured News & Press Releases 41
Oct 02, 2012: Merrimack Pharma Presents Phase I Study Of MM-121 At European Society For Medical Oncology 2012 41
Dec 28, 2011: Researchers Reveal Targeted Therapy Extends Progression-Free Survival Of Patients With Advanced Ovarian Cancer 42
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 45
Disclaimer 45

List of Tables
Number of Products Under Development for Metastatic Ovarian Cancer, H2 2012 7
Products under Development for Metastatic Ovarian Cancer – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
F. Hoffmann-La Roche Ltd., H2 2012 16
Sanofi-Aventis, H2 2012 17
Daiichi Sankyo Company, Ltd, H2 2012 18
Cell Therapeutics, Inc., H2 2012 19
Northwest Biotherapeutics, Inc., H2 2012 20
NewLink Genetics Corporation, H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 27
Metastatic Ovarian Cancer Therapeutics – Drug Profile Updates 39
Metastatic Ovarian Cancer Therapeutics – Dormant Products 40

List of Figures
Number of Products under Development for Metastatic Ovarian Cancer, H2 2012 7
Products under Development for Metastatic Ovarian Cancer – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 22
Assessment by Combination Products, H2 2012 23
Assessment by Route of Administration, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 25
Assessment by Molecule Type, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 27

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos